Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 59

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 59
---
 Yehezkel Barenholz at the Hebrew University of Jerusalem.

Product Pipeline

The Company, through LipoVation, is developing a portfolio of NLP-based pharmaceutical candidates and plans to complete the development and commercialization of a series of medical technologies including:

| ● | Nanoparticles-based                                                                                 
 formulation of a potent antibiotic which, based on in vitro and in vivo animal                      
 models studies, shows promising potential in combating severe life-threatening antibiotic-resistant 
 bacteria;                                                                                           |

| ● | Novel                                                                                            
 adjuvant to cancer therapies: a nanoparticles-based formulation of angiotensin receptor blockers 
 (ARB) for intravenous administration;                                                            |

| ● | Liposomal                                                                                          
 Protein-Loaded Technology (LPLT): a novel approach in immunization through innovative nano         
 particle-based vaccines, which we believe has the potential to be more durable and efficient       
 than mRNA vaccines and will provide longer-lasting protection together with broader cross-immunity 
 to protect against new virus variants.                                                             |

However, even if preclinical studies may show promising results, there is no guarantee that such pharmaceutical candidate will demonstrate sufficient efficacy in human populations.

Industry Overview and Market Opportunities

Nanoparticles-based therapies, also referred to as nanomedicines or nano delivery systems, are employed to serve as means of diagnostic tools or to deliver therapeutic agents to specific targeted sites in a controlled manner. Nanotechnology offers multiple benefits in treating chronic human diseases by site-specific, and target-oriented delivery of precise medicines. These include several chemotherapeutic agents, biological agents, and immunotherapeutic agents.

Nanoparticles-based liposomal therapeutics have been developed to improve the therapeutic index of new or established drugs by modifying drug absorption, reducing metabolism, prolonging biological half-life or reducing toxicity. Nanostructures stay in the blood circulatory system for a prolonged period and enable the release of amalgamated drugs as per the specified dose. Thus, they cause fewer plasma fluctuations with reduced adverse effects. 1Being nanosized and optionally “decorated” with active moieties, these structures could potentially penetrate into tumour environment (Enhance permeability and retention – “EPR” effect) or other inflamed tissues, facilitate easy uptake of the drug by cells, permit an efficient drug delivery, and ensure action at the targeted location. The uptake of nanostructures by cells is much higher than that of large particles with size ranging between 1 and 10 µm. Hence, they directly interact to treat the diseased cells with improved efficiency and reduced or negligible side effects